Login to Your Account

Deals And M&A NEWS

With "our crown jewel back in our hands and the opportunity to bring it all the way to the market," Symphogen A/S found cause to celebrate, said CEO Kirsten Drejer, as the firm makes plans to finish the phase IIb trial begun by Merck KGaA with Sym004.


As company backers await data from the phase I trial with CUDC-907, due in June at the American Society of Clinical Oncology (ASCO), Curis Inc. signed an immuno-oncology deal that could be worth more than $100 million to Aurigene Discovery Technologies Ltd.

Just last week, Celgene Corp.'s head of business development, George Golumbeski, told a packed breakout session at the annual J.P. Morgan Healthcare Conference in San Francisco that the firm's long-term pipeline "can never be big enough."

More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: